Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vigonvita Life Sciences Co's Days Sales Outstanding for the
six
months ended in Dec. 2025 was 27.04.
Vigonvita Life Sciences Co's Days Inventory for the
six
months ended in Dec. 2025 was 80.74.
Vigonvita Life Sciences Co's Days Payable for the
six
months ended in Dec. 2025 was 78.87.
Therefore, Vigonvita Life Sciences Co's Cash Conversion Cycle (CCC) for the
six
months ended in Dec. 2025 was 28.91.
Vigonvita Life Sciences Co (HKSE:02630) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Vigonvita Life Sciences Co Cash Conversion Cycle Related Terms
Vigonvita Life Sciences Co Cash Conversion Cycle Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vigonvita Life Sciences Co Cash Conversion Cycle Chart
Vigonvita Life Sciences Co Annual Data
Trend
Dec23
Dec24
Dec25
Cash Conversion Cycle
224.24
765.41
28.91
Vigonvita Life Sciences Co Semi-Annual Data
Dec23
Dec24
Dec25
Cash Conversion Cycle
224.24
765.41
28.91
HKSE:02630 vs LLY, JNJ, ABBV: Cash Conversion Cycle Comparison
For the Drug Manufacturers - General subindustry, Vigonvita Life Sciences Co's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vigonvita Life Sciences Co Cash Conversion Cycle vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vigonvita Life Sciences Co's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Vigonvita Life Sciences Co's Cash Conversion Cycle falls into.
Vigonvita Life Sciences Co Cash Conversion Cycle Calculation
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Vigonvita Life Sciences Co's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vigonvita Life Sciences Co (HKSE:02630) has a Cash Conversion Cycle of 28.91 as of Dec. 2025. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Vigonvita Life Sciences Co and its competitors.
Is Vigonvita Life Sciences Co's Cash Conversion Cycle too high?
Vigonvita Life Sciences Co's current Cash Conversion Cycle is 28.91. The Drug Manufacturers industry median Cash Conversion Cycle is 145.82. Vigonvita Life Sciences Co's value of 28.91 is 80.2% below this industry median. Overall, Vigonvita Life Sciences Co has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Vigonvita Life Sciences Co's Cash Conversion Cycle compare to LLY and JNJ?
Vigonvita Life Sciences Co's Cash Conversion Cycle of 28.91 can be compared against companies in the Drug Manufacturers industry. The industry median Cash Conversion Cycle is 145.82. Vigonvita Life Sciences Co's value of 28.91 is 80.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Drug Manufacturers company?
The median Cash Conversion Cycle among Drug Manufacturers companies is 145.82, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vigonvita Life Sciences Co's current Cash Conversion Cycle of 28.91 is 80.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Vigonvita Life Sciences Co and its competitors. For the Drug Manufacturers industry, the median Cash Conversion Cycle is 145.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vigonvita Life Sciences Co's current Cash Conversion Cycle is 28.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vigonvita Life Sciences Co stock overvalued right now?
Vigonvita Life Sciences Co (HKSE:02630) has a current Cash Conversion Cycle of 28.91. The current Cash Conversion Cycle is 28.91 and 80.2% below the Drug Manufacturers industry median of 145.82. Vigonvita Life Sciences Co's overall GF Score™ is 8/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Vigonvita Life Sciences Co (HKSE:02630), the current Cash Conversion Cycle is 28.91 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vigonvita Life Sciences Co Ltd biopharmaceutical company. It is focused on innovation driven biopharmaceutical development, with a strategic emphasis on addressing unmet clinical needs in the treatment of neuropsychiatric, infectious, and andrological diseases. The company's core Products include LV232, anti-depression drug candidate, VV913: a novel investigational drug candidate for premature ejaculation and, VV116: an oral nucleoside analog with broad-spectrum antiviral potential. The company's operations are located in the PRC and Uzbekistan. Revenue is generated from the out-licensing and the sales of its pharmaceutical products.
8GF Score
Get the complete analysis for HKSE:02630
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02630 has been successfully added to your 
